Cancer drugs from Novartis and Pfizer also backed
Concerns that NICE will reject Kisqali like it did Ibrance.
Companies hope tanezumab offers alternative to opioids
FDA grants faster and development and review process.
Upadacitinib hopes drug will reduce reliance on Humira.
Target is implicated in a number of nervous system diseases.
Biotech insists drug for rare inherited disorder is still approvable.